Table 2.
Clinical trials for COVID-19 treatment using human placenta MSCs
| Clinical trial ID | Title | Cell type | Status | Phase | Outcome measures | Locations |
|---|---|---|---|---|---|---|
| NCT04390139 | Efficacy and safety evaluation of mesenchymal stem cells for the treatment of patients with respiratory distress due to COVID-19 | WJ-MSCs | Recruiting | 1; 2 |
-All-cause mortality at day 28. -Safety of WJ-MSC. -Need for treatment with rescue medication. -Ventilator free days. -Duration of hospitalization. -Evolution of markers of immune response. -And 9 more. |
Spain |
| NCT04456361 | Use of mesenchymal stem cells in acute respiratory distress syndrome caused by COVID-19 | WJ-MSCs | Active, not recruiting | 1 |
-Oxygen saturation. -Oxygen pressure in inspiration. -Ground-glass opacity. -Pneumonia infiltration. -And 4 more. |
Mexico |
| NCT04313322 | Treatment of COVID-19 patients using Wharton’s jelly-mesenchymal stem cells | WJ-MSCs | Recruiting | 1 |
-Clinical outcome. -CT Scan. -RT-PCR results. |
Jordan |
| NCT04461925 | Treatment of coronavirus COVID-19 pneumonia pathogen SARS-CoV-2) with cryopreserved allogeneic P-MMSCs and UC-MMSCs | P-MMSCs | Recruiting | 1; 2 |
-Changes in length of hospital stay. -Changes in mortality rate. -Evaluation of pneumonia improvement. -Peripheral blood count recovery time. -And 3 more. |
Ukraine |
| NCT04565665 | Cord blood-derived mesenchymal stem cells for the treatment of COVID-19 related acute respiratory distress syndrome | CB-MSCs | Recruiting | 1 |
-Incidence of composite serious adverse events. -Overall survival rate. -Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters. -And 10 more. |
USA |
| NCT04494386 | Umbilical cord lining stem cells (ULSC) in patients with COVID-19 ARDS | ULSCs | Recruiting | 1; 2 |
-Incidence of dose limiting toxicity. -Changes in levels of blood glucose (mg/dL) from baseline. -Changes in levels of sodium and potassium (mEq/L) from baseline. -And 9 more. |
USA |
| NCT04573270 | Mesenchymal stem cells for the treatment of COVID-19 | UC-MSCs | Completed | 1 |
-Survival rates. -Contraction rates |
USA |
| NCT04288102 | Treatment with human umbilical cord-derived mesenchymal stem cells for severe corona virus disease 2019 (COVID-19) | UC-MSCs | Completed | 2 |
-Change in lesion, ground-glass, or consolidation lesion proportion of full lung volume from baseline to day 10, 28, and 90. -Time to clinical improvement. -And 5 more. |
China |
| NCT04355728 | Use of UC-MSCs for COVID-19 patients | UC-MSCs | Completed | 1; 2 |
-Incidence of pre-specified infusion associated adverse events. -Incidence of severe adverse events. -Survival rate after 90 days post first infusion. -Ventilator-free days. -Change in oxygenation index. -And 11 more. |
USA |
| NCT04252118 | Mesenchymal stem cell treatment for pneumonia patients infected with COVID-19 | UC-MSCs | Recruiting | 1 |
-Size of lesion area by Chest radiograph or CT. -Time of nucleic acid turning negative. -CD4+ and CD8+ T cell count. -And 6 more |
China |
| NCT04416139 | Mesenchymal stem cell for acute respiratory distress syndrome due for COVID-19 | UC-MSCs | Recruiting | 2 |
-Changes in body temperature. -General biochemical changes in Leukocytes. -Functional respiratory change: PaO2/FiO2 ratio. -And 23 more. |
Mexico |
| NCT04437823 | Efficacy of intravenous infusions of stem cells in the treatment of COVID-19 patients | UC-MSCs | Recruiting | 2 |
-Safety and efficacy assessment of infusion associated adverse events. -Chest radiograph or CT scan. -COVID-19 QRT-PCR. -And 3 more. |
Pakistan |
| NCT04333368 | Cell therapy using umbilical cord-derived mesenchymal stromal cells in SARS-CoV-2-related ARDS | UC-MSCs | Recruiting | 1; 2 |
-Lung injury score. -Oxygenation index. -In-hospital mortality. -Mortality. -Ventilator-free days. -Cumulative use and duration of sedatives. -And 9 more. |
France |
| NCT04366063 | Mesenchymal stem cell therapy for SARS-CoV-2- related acute respiratory distress syndrome | UC-MSCs | Recruiting | 2; 3 |
-Adverse events assessment. -Blood oxygen saturation. -Clinical symptoms. -Respiratory efficacy. -Biomarker concentrations. -Intensive care unit-free days. |
Republic of Islamic |
| NCT04339660 | Clinical research of human mesenchymal stem cells in the treatment of COVID-19 Pneumonia | UC-MSCs | Recruiting | 1; 2 |
-The immune function. -Blood oxygen saturation. -Duration of respiratory symptoms. -COVID-19 nucleic acid negative time. -And 4 more. |
China |
| NCT03042143 | Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) (COVID-19) | UC-MSCs | Recruiting | 1; 2 |
-Respiratory compliance. -Oxygenation index. -Driving pressure. -Extubation and reintubation. -Ventilation free days at day 28. -And 6 more. |
UK |
| NCT04399889 | hCT-MSCs for COVID19 ARDS | UC-MSCs | Recruiting | 1; 2 |
-Survival after 28 days after the first dose of MSCs. -The number of ventilator free days. -And 8 more. |
USA |
| NCT04269525 | Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) Treatment for the 2019-novel coronavirus (nCOV) pneumonia | UC-MSCs | Recruiting | 2 |
-Oxygenation index. -28 days mortality. -Hospital stays. 2019-nCoV antibody test. -2019-nCoV nucleic acid test. -Improvement of lung imaging examinations. -And 13 more. |
China |
| NCT04366271 | Clinical trial of allogeneic mesenchymal cells from umbilical cord tissue in patients with COVID-19 (MESCEL-COVID19) | UC-MSCs | Recruiting | 2 |
-Mortality from any cause at 28 days. -Patients alive and without mechanical ventilation on day 14. -Patients cured at 15 days. -And 8 more. |
Spain |
| NCT04371601 | Safety and effectiveness of mesenchymal stem cells in the treatment of pneumonia of coronavirus disease 2019 | UC-MSCs | Active, not recruiting | 1 |
-Changes of oxygenation index. -Detection of TNF-α, IL-10 levels. -Immune cell detection. -And 2 more. |
China |
| ChiCTR2000031430 | Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis | UC-MSCs | Recruiting | 2 |
-Coagulation. -High resolution CT for chest. -Blood gas analysis. -Blood routine. -Cytokine analysis. -And 16 more. |
China |
MSCs mesenchymal stromal cells, WJ-MSCs Wharton’s Jelly mesenchymal stem cells, P-MMSCs placenta-derived multipotent mesenchymal stromal cells, CB-MSCs cord blood-derived mesenchymal stem cells, ULSCs umbilical cord lining stem cells, UC-MSCs umbilical cord mesenchymal stem cells